Bristol investigation expands
Executive Summary
Investigation of Bristol-Myers Squibb by the New Jersey U.S. Attorney "has expanded to include a review of whether there was any violation of Federal securities laws in connection with the proposed settlement with Apotex" under the terms of a 2004 consent order with the Securities & Exchange Commission, the company says in its third quarter earnings release Oct. 26. The U.S. Attorney is investigating governance issues relating to the company's negotiations with Apotex; Bristol's failed settlement with Apotex over generic Plavix may impact the company's compliance with a deferred prosecution agreement with the New Jersey U.S. Attorney. The Department of Justice is also conducting a criminal investigation of the proposed settlement (1"The Pink Sheet" Aug. 14, 2006, p. 3)...
You may also be interested in...
Bristol May Be An Acquisition Target Following Entry Of Plavix Generics
The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.